Drug Discovery

Teach Me in 10

In this exclusive Teach Me in 10, Dr. James Goldmeyer, Associate Director at Revvity, delves into the transformative impact of functional genomic screening in the realm of drug discovery. Revvity, a leader in the field, provides comprehensive solutions spanning research, development, diagnosis, and treatment. Dr. Goldmeyer, with his extensive experience, sheds light on the potential applications and outcomes of this cutting-edge technique.

Viewers will gain an understanding of how this technique works and the tools involved, including CRISPR-based technologies and RNA interference. Dr.Goldmeyer explains how these components synergize to form a robust platform for researchers. The interview explores how this approach benefits researchers in their quest for novel therapies. Notably, functional genomic screening bridges the gap left by traditional methods, enabling the development of personalized treatments with greater precision and detail. 

The discussion further illuminates the pivotal role of functional genomic screening in various stages of drug discovery. The technique aids in target identification, elucidating drug response mechanisms, and unraveling in vivo tumor biology. Despite its numerous advantages, potential disadvantages are also examined, contributing to a well-rounded understanding of the approach. 

Revvity's specialized focus on gene modification is highlighted, with emphasis on potential applications and diseases that stand to benefit. The interview explores how functional genomic screening not only accelerates drug discovery but also lends itself to the development of innovative cell-based therapies.

Unlocking New Cures: How Functional Genomic Screening Revolutionizes Drug Discovery

Biotech Videos 

Immunotherapy has become a novel, powerful clinical strategy of cancer treatment. The number of immunotherapy drug approvals is increasing, with numerous therapeutics in clinical and preclinical development. 
https://www.creative-biolabs.com/drug-discovery/therapeutics/target-discovery-for-cancer-immunotherapy.htm

Immune Cell Migration in Cancer and Immunotherapy

Genome editing, also known as gene editing, is the insertion, deletion or replacement of DNA at a specific site in the genome of an organism or cell. Gene silencing refers to prevent the expression of a certain gene. Both of these two approaches have been effectively used in a wide variety of tissues and organisms to study how genome influences phenotype.
https://www.creative-biolabs.com/drug-discovery/therapeutics/gene-manipulation.htm



Gene Manipulation

Transposons-based genetic strategies have been established in vertebrate species over the last decade. The major advantage of these strategies is that they facilitate analysis of gene function in an easy, controlled, and scalable manner, thereby avoiding some of the limitations of the classical DNA microinjection method. 
https://www.creative-biolabs.com/drug-discovery/therapeutics/transposon-mediated-genome-manipulation.htm

Gene Delivery Systems

Rational optimization of the antibody molecule by Fc engineering represents a major area of translational research to further improve this potent therapeutic option. 
https://www.creative-biolabs.com/drug-discovery/therapeutics/effector-function-improvement-via-antibody-skeleton-engineering.htm

Effector Functions-enhanced Antibodies

Creative Biolabs provides professional custom service packages to fully meet client's specific needs in drug development journey, especially for various antibody related modalities (monoclonal antibody, single domain antibody, bispecific antibody, multi-specific antibody, ADC, CAR T, etc.). Creative Biolabs generates antibodies against different targets ranging from hapten, soluble protein, membrane protein and whole cells, using well established multiple platforms such as hybridoma, phage display and B cell sorting for novel antibody discovery, enabling to provide the most suitable approach to the client's project. What makes Creative Biolabs distinguished from competitors is that we proceed clients' projects according to their specific demands in quality, timeline and budget, supporting researchers across different therapeutic areas. Clear, open and regular communication with customers is as important to our success as our in-depth scientific knowledge. Having carved a unique niche by scripting many such success stories, Creative Biolabs' services are expanding from antibody discovery and development to a broader area, including immunotherapy and cell and gene therapies.
https://www.creative-biolabs.com/

Your Biopharmaceutical Discovery Partner

Cysteine residues serve essential roles in protein structure and function due to their highly reactive thiol side chains that form inter or intra molecular di-sulfide bonds to enable correct protein folding.
https://www.creative-biolabs.com/adc/cysteine-based-conjugation.htm

Cysteine Based Conjugation

During this presentation, we will discuss environmental monitoring, including regulatory expectations, and briefly present our Applied Biosystems MicroSEQ™ Rapid microbial identification system.  Used in top pharmaceutical companies worldwide, the microbial identification system is an end-to-end rapid genotypic sequencing solution, based on ribosomal gene sequencing for bacterial and fungal species-level identification, generating accurate results in less than 5 hours.

The Science Behind Pristine Production: Environmental Monitoring in Biopharmaceutical Facilities

Oncotarget

Oncotarget published this trending editorial on September 15, 2023 in Volume 14, entitled, “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma" by Kuniko Horie and Satoshi Inoue from the Division of Systems Medicine and Gene Therapy, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi-ku, Tokyo, Japan.

DOI - https://doi.org/10.18632/oncotarget.28463

Correspondence to - Satoshi Inoue -  sinoue07@gmail.com

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28463

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, renal cell carcinoma (RCC), tyrosine kinase inhibitor (TKI), Dipeptidyl peptidase IV (DPP4), drug resistance, drug repurposing

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Drug Discovery

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.